Benjamin F. Edwards & Company’s Sage Therapeutics SAGE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-183	Closed	-$8K	–	1830
2021 Q4	$8K	Hold	183	–	–	﹤0.01%	1438
2021 Q3	$8K	Hold	183	–	–	﹤0.01%	1437
2021 Q2	$10K	Hold	183	–	–	﹤0.01%	1389
2021 Q1	$14K	Hold	183	–	–	﹤0.01%	1287
2020 Q4	$16K	Hold	183	–	–	﹤0.01%	1190
2020 Q3	$11K	Hold	183	–	–	﹤0.01%	1259
2020 Q2	$8K	Hold	183	–	–	﹤0.01%	1340
2020 Q1	$5K	Hold	183	–	–	﹤0.01%	1441
2019 Q4	$13K	Hold	183	–	–	﹤0.01%	1353
2019 Q3	$26K	Buy	183 +50	+38%	+$8.36K	﹤0.01%	1114
2019 Q2	$24K	Hold	133	–	–	﹤0.01%	1140
2019 Q1	$21K	Sell	133 -167	-56%	-$24.2K	﹤0.01%	1123
2018 Q4	$29K	Buy	+300	New	+$34.3K	﹤0.01%	992

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Benjamin F. Edwards & Company's SAGE Position: Q1 2022 in Review

Benjamin F. Edwards & Company sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 183 shares — an estimated $8K sold.

Benjamin F. Edwards & Company first reported a position in SAGE in Q4 2018 and held it in 13 quarters. The position peaked at $29K in Q4 2018. 212 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

Benjamin F. Edwards & Company reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
Benjamin F. Edwards & Company sold 183 Sage Therapeutics shares in Q1 2022, an estimated $8K.
Benjamin F. Edwards & Company first reported a position in Sage Therapeutics in Q4 2018 and held it in 13 quarters.
Benjamin F. Edwards & Company's Sage Therapeutics position peaked at $29K in Q4 2018.
212 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2022, filed 4 May 2022.